Delcath Systems price target lowered to $30 from $31 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Delcath Systems (DCTH) to $30 from $31 and keeps a Buy rating on the shares after the company issued preliminary Q3 financial results and lowered revenue guidance for FY2025. Additionally, Delcath presented a clinical data update from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 annual Congress of European Society for Medical Oncology, notably that the clinical study met its primary endpoint of improved one-year progression-free survival.